Products SEO & GEO Agent Paid Ads Agent Website Agent Conversion Agent
How it works Pricing FAQ Blog Book a call

Biotech content writing for scientists, investors and patients

Updated · 8 min read

Short answer Write each claim once, as precisely as your data allows, then adapt it for each reader without making it stronger. Scientists get methods and limits. Investors get milestones with risks attached, released to everyone at once. Patients get plain words and no promise that an unapproved product works. A scientist, an editor and a regulatory reviewer sign off before anything goes live.

Want help applying this to your business? Talk it through on a free 30-minute call.

Book a call

One claim, three readers

Most biotech companies talk to three groups at once, and each one breaks a different rule if you get it wrong.

ReaderWhat they askWhat to give themThe rule that bites
Scientists and cliniciansDoes the data hold up?Methods, sample size, controls, limits, the full datasetFDA and Health Canada limits on promoting unapproved products
InvestorsWhat's next, and what could go wrong?Milestones, timelines, risks, cash runwaySEC Regulation FD, forward-looking statement rules, anti-fraud law
Patients and the publicCan this help me, and can I join?Plain words, the trial's status, how to take partFDA expectations for trial recruitment ads

Start from a single sentence your data supports, such as "In a 40-patient Phase 1 trial, the drug was tolerated at all doses tested." Every version for every reader comes from that sentence. Shorter is fine. Stronger is not.

The rule under every piece: no promotion before approval

Until a drug is approved, the US rule is short:

"A sponsor or investigator, or any person acting on behalf of a sponsor or investigator, shall not represent in a promotional context that an investigational new drug is safe or effective for the purposes for which it is under investigation or otherwise promote the drug." (21 CFR 312.7)

The same section protects science. It "is not intended to restrict the full exchange of scientific information concerning the drug, including dissemination of scientific findings in scientific or lay media." So you may report what a study found. You may not sell the drug as safe or effective.

In Canada, no one may "sell or advertise a new drug" until Health Canada has issued a notice of compliance for it (Food and Drug Regulations, C.08.002). Health Canada's 2023 guidance says a message that does not promote the sale of a health product is not subject to the advertising rules, and it treats a researcher speaking at a conference with a varied agenda as an example of the non-promotional side. Messages about unapproved products or uses can still count as promotion depending on context, so each one is judged case by case.

Practical test for every page: would a reader come away thinking the product works and they should want it? If yes, it's promotion.

Writing for scientists: show the work

Scientists trust content that lets them judge the data themselves.

  • Say what kind of evidence it is: peer-reviewed paper, preprint, conference poster, or internal data. Label each one.
  • Give the numbers that matter: how many patients or samples, what you compared against, the primary endpoint, and what didn't work.
  • Report the whole result. If you highlight a subgroup, say it's a subgroup and give the full-population result next to it.
  • Name the author and their role, including any stake in the product. How Google weighs who wrote a page: E-E-A-T for a small business.

The last two points aren't just style. In 2024 the SEC charged Cassava Sciences and two former executives over a Phase 2 Alzheimer's announcement. The SEC said the company "failed to disclose that the full set of patient data – as opposed to the subset of data hand-selected by Burns – showed no measurable cognitive improvement," and that a co-inventor with a financial interest in the drug had tested the samples without being blinded. The company and the two executives agreed to civil penalties of $40 million, $175,000 and $85,000 without admitting or denying the claims (SEC Litigation Release 26132).

Writing for investors: same news, same moment, risks attached

Investor content covers pipeline updates, trial readouts, financing news and the company story. Three rules shape it.

Tell everyone at once (US public companies). Under Regulation FD, if a public company shares material nonpublic information with analysts, investment firms or shareholders likely to trade on it, it must make that information public at the same time when the sharing is deliberate, or promptly when it's accidental (17 CFR 243.100). A readout belongs in a press release or filing first, not in a private deck. Social media can count as public, the SEC said in 2013, "so long as investors have been alerted about which social media will be used to disseminate such information" (SEC press release 2013-51). An executive's personal account usually won't count on its own.

Label the future as the future. US law protects a forecast that is "identified as a forward-looking statement, and is accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially" (15 U.S.C. 78u-5). The protection doesn't cover statements made in connection with an initial public offering, so pre-IPO content needs extra care.

Canada: a reporting issuer may disclose forward-looking information only with "a reasonable basis" for it. Material forward-looking information must be identified as such, carry cautions and the main risk factors, and state the key assumptions behind it (National Instrument 51-102, Part 4A).

In practice: "We expect Phase 2 data in the second half of 2027" sits next to a short list of what could delay it, such as enrollment, manufacturing or a regulator's request for more data.

Regulation FD covers only companies registered with or reporting to the SEC (17 CFR 243.101). A private company raising money is still under Rule 10b-5, which makes it unlawful "to make any untrue statement of a material fact" or leave out a fact needed to keep a statement from misleading, in connection with buying or selling any security (17 CFR 240.10b-5).

Writing for patients: plain words, no promises

Patients come with a condition, not a vocabulary. Use everyday words, explain each technical term once, and say clearly whether the product is approved, in trials, or still in the lab.

  • Compare to something familiar, then say where the comparison stops. "Gene editing works like find-and-replace in a document" helps only if you add that it can miss or hit the wrong spot.
  • Draw it. A simple diagram of how the drug acts, or a timeline of trial phases, often beats a paragraph.
  • Test it on an outsider. If a friend outside science can't say the main point back, rewrite.

If the goal is trial enrollment, the FDA treats the ad as part of consent: "FDA considers direct advertising for study subjects to be the start of the informed consent and subject selection process." Its guidance says recruitment ads should go to the ethics board (IRB) for review and approval, and sets out what to avoid:

AvoidWhy
Saying or implying the product is safe or effectiveThe trial exists to find out
"New treatment," "new medication" or "new drug," with no word that it is investigationalImplies proven benefit
"Free medical treatment" when you mean there's no charge to take partMisleads about what participants get

What the FDA says an ad may include, when worded carefully: the investigator or site name and address, the condition and purpose of the study, a short summary of eligibility, a brief list of benefits such as a no-cost health exam, the time commitment, and who to contact (FDA: Recruiting Study Subjects).

Patient stories need written permission and a regulatory check. A story about feeling better on an investigational drug is a safety-and-effectiveness claim in someone else's words.

The review step: who checks what before publishing

Biotech teams usually call this medical, legal and regulatory review. A small company can run it with three people, as long as each one has a clear job.

ReviewerChecksSigns off when
Scientist (subject matter expert)Every number matches its source; the evidence type is labeled; limits are statedEach claim points to a paper, poster, filing or data file
EditorReads at the right level for the audience; terms explained; one message per pieceA person outside the field can say back the main point
Regulatory or legalNo promotion of unapproved products or uses; forward-looking language and risks; consent for stories and namesThe piece passes the "would they want it?" test above

Keep a simple claims log: the claim, its source, who checked it, and the date. Re-check old pages when new data comes in or a trial changes status. A page that says "enrolling" a year after the trial closed is wrong. How to refresh or retire old pages: content decay.

If AI drafts any of it, the same review applies. Google's view on AI-written pages: does Google penalize AI content.

After approval: the rules change, they don't go away

Once a US prescription drug is approved, its ads must give a fair balance between benefits and risks. An ad breaks the rule if effectiveness is "presented in greater scope, depth, or detail" than the side effects and contraindications (21 CFR 202.1).

In Canada, ads for prescription drugs aimed at the public are limited to the brand name, proper name, common name, price and quantity (Food and Drug Regulations, C.01.044). Content for patients there stays educational, not promotional.

Example

A 15-person company with a Phase 1 readout

The scientist writes one sentence from the data. It becomes a press release and an SEC filing at the same moment, with expected next steps and risks. A scientific poster summary goes on the site for researchers. A patient page explains, in plain words, what Phase 1 tests and that the drug is not approved.

A private Canadian startup raising its first round

Its investor deck says "Phase 2 start expected in 2027" and lists the assumptions behind that date: financing closes, manufacturing scales, and Health Canada accepts the trial application. Its website describes the science but never says the drug works.

A company recruiting for a Phase 2 trial

Its first ad draft says "Try a new treatment for free." After review, it reads: "Researchers are studying an investigational drug for adults with [condition]. Study visits and tests are at no cost." The IRB approves it before it runs.

FAQ

Can a biotech company blog about a drug that isn't approved?

Yes, about the science and the study, if it never presents the drug as safe or effective. 21 CFR 312.7 keeps scientific exchange open.

Should we write separate pages for scientists and patients?

Usually. One page ends up too technical for patients or too thin for scientists. Link the two so each reader can switch.

Does a private biotech need forward-looking statement language?

Regulation FD doesn't apply, but Rule 10b-5 bans misleading statements in any securities sale, private rounds included. Labeling forecasts and stating risks is the safe habit.

How often should we update science pages?

Whenever new data, a trial status change or a regulatory decision makes a page wrong. Put the review date on each page.

Different for you?

Keep learning

NextRetailTech SEO: product and category pages retail buyers findRetailTech SEO for companies selling software or hardware to stores: the product, category and integration pages retail buyers search for, from Google's rules.

Ask us one question

One line is enough. We reply by email.

Sources

  1. 21 CFR 312.7: Promotion of investigational drugs (eCFR)
  2. Food and Drug Regulations, C.08.002 (Justice Laws)
  3. Health Canada: Guidance on distinction between advertising and other activities for health products (2023)
  4. 17 CFR 243.100: Regulation FD, general rule regarding selective disclosure (eCFR)
  5. 17 CFR 243.101: Regulation FD definitions (eCFR)
  6. 17 CFR 240.10b-5: Employment of manipulative and deceptive devices (eCFR)
  7. SEC press release 2013-51: SEC Says Social Media OK for Company Announcements if Investors Are Alerted (April 2, 2013)
  8. 15 U.S.C. 78u-5: Safe harbor for forward-looking statements (Cornell LII)
  9. National Instrument 51-102 Continuous Disclosure Obligations, Part 4A (BCSC, effective September 22, 2026)
  10. SEC Litigation Release 26132: Cassava Sciences, Remi Barbier and Lindsay Burns (September 26, 2024)
  11. FDA: Recruiting Study Subjects, guidance for IRBs and clinical investigators
  12. 21 CFR 202.1: Prescription drug advertisements (eCFR)
  13. Food and Drug Regulations, C.01.044 (Justice Laws)